World Orphan Drug Orphan Congress Agenda
Barcelona, 12 - 14 November 2019
Schedule
Create your personal agenda –check the favourite icon
Nov 1210:00
Conference pass
Workshop A: Balancing on the Edge – Value Evidence and Market Access for Orphan Drugs in the US and EU
Keynotes
- Getting the right balance
- Drug development decisions are primarily based on commercial opportunities; US, EU and other geographies tend to have different requirements and offer different opportunities
- Orphan Drugs and Oncology Orphans: Time to access and availability in the US and EU5
- Success stories and remarkable failures may tell us interesting lessons
- Paths to Optimal Evidence Generation Plans for ODs
- Gathering payers’ and HTA agencies’ requirements as part of a company’s evidence generation plan, designed to achieve access and not just regulatory approval
- From theory to reality: ‘Innovative’ approaches to gross to net pricing
- US contracting and EU managed entry agreements may allow to achieve an acceptable balance between access and budget constraints
- Optimal evidence vs. Market Access risk: Is there an optimal balance?
- Industry and HTA Bodies’ have different perspectives, but a compromise is needed for patients to access new promising OD therapies
Nov 1210:00
Conference pass
Workshop B: Drug Repurposing Use for Orphan Drugs Industry vs patient rep & off-label vs label use: Transparency, incentives and approaches to help industry repurpose
Keynotes
- Off-label Prescribing: Justifying Unapproved Medicine
- Results from an off-label study and its impact in AKU patients in parallel with the international clinical trial
- Update on STAMP
- Industry perspective
- Incentivising generics manufacturers to repurpose drugs
- Generics of ex-orphan drugs: Uses and controversies
Nov 1214:00
Conference pass
Workshop C: Overcoming Clinical & Regulatory challenges in ATMPs
Keynotes
This workshop provides expert guidance and practical case studies to help address the major challenges of:· Drug candidate early development· Regulatory strategy & Trial design· Real patient engagement & Market access· Unique challenges in the manufacturing and commercialization of gene therapies for rare diseases
Annie Hubert, Director, European Public Policy, Alliance for Regenerative Medicine
Nov 1214:00
Conference pass
Workshop D: Gene and cell therapies in rare diseases: creating a sustainable business model and pathway to patient access
Keynotes
The full potential of innovative new gene and cell therapies will only be realised through the creation of a sustainable business model and a clear pathway to access for rare disease patients. Dolon’s interactive workshop provides you with the opportunity to explore the complexities of pricing an orphan drug, using a series of exercises that explore the orphan drug business model, how pricing and investment decisions are made, and how policy impacts innovation.The RARE-IMPACT initiative, chaired by Eurordis and supported by Dolon, is a consortium of rare disease manufacturers that is engaging with HTA agencies, regulatory bodies, payers, patient groups, clinicians and other experts across Europe, to identify and validate the challenges to patients’ access to gene and cell therapies.
Create your personal agenda –check the favourite icon
Nov 1308:25
Conference pass
What incentives are available for developing orphan drugs? Is the current orphan drug legislation & incentives enough?
Keynotes
- Findings from the commission’s value assessment evaluation report – should guidelines be amended?
- Feedback and alignment from regulators and industry
- Considerations in the unaccounted costs for industry, society values of orphan drugs and the role of competition
- Are our policy makers direction in line with what society wants?
Ulrika Vestin, Swedish Association of Local Authorities and Regions
Nov 1309:10
Conference pass
What guidance can we give industry when working with European Reference Networks (ERNs) and R&D?
Keynotes
- Roadmap for industry: How should industry be engaging with ERNs and what does each have to offer to improve clinical and research aspects?
- Company and ERN perspectives, experiences so far
- What can we learn from US CRNs?
- How can ERNs & CRNs collaborate?
- Stakeholder engagement with ERNs – industry and patients beyond academic and clinical networks
Nov 1309:55
Conference pass
Executive Insights: What technologies need to be unlocked? Discussing all the scientific aspects that are impacting the reality of gene therapy
Keynotes
- What is the science driving your business model, how do we overcome the technological constraints?
- Challenges in creating robust pipelines sustainable to patients (selecting indications, tissue targeting/distribution, immunogenicity, limitations of vectors)
- How have gene therapies in the past influenced our current pipelines?
- Realities of manufacturing & commercialisation
Nov 1311:30
Conference pass
11:30 – 12:15: Roundtable and Q&As on plenary orphan drug legislation & incentives
Keynotes
Nov 1311:30
Conference pass
Balance between medical and promotional (sales force) in achieving brand objectives in rare diseases
Keynotes
Nov 1311:30
Conference pass
Best practices and tools to get patients groups to fully engaged
Keynotes
Nov 1311:30
Conference pass
Building a new infrastructure for long term evidence generation with use of registries
Keynotes
Nov 1311:30
Conference pass
Expediting drug development in rare disease: Are big data and biomarkers an option for the future?
Keynotes
Nov 1311:30
Conference pass
Gene editing revolution: Hope for rare diseases, but should there be limits?
Keynotes
Nov 1311:30
Conference pass
How can we overcome the clinical development challenges facing advanced therapies for rare diseases?
Keynotes
Nov 1311:30
Conference pass
Leveraging patient-focused technological solutions to support better diagnosis and access to new treatments for rare disease patients
Keynotes
Nov 1311:30
Conference pass
Market entry strategies for orphan drugs in Central Eastern Europe
Keynotes
Nov 1311:30
Conference pass
Patient organizations as partners: Including “resource” issues from support for education to support for supporting patient communities
Keynotes
Nov 1311:30
Conference pass
The impact of Brexit and Europe-wide effects from market access to the UK, patient collaborations across Europe
Keynotes
Nov 1311:30
Conference pass
The Italian experience: How has our experience changed how we manage ODs?
Keynotes
Nov 1311:30
Conference pass
The patient voice: An important consideration not only for late stage reimbursement, but also for early stage regulatory affairs
Keynotes
Nov 1312:20
Conference pass
12:20 – 13:05 Roundtable and Q&As on plenary ERNs
Keynotes
Nov 1312:20
Conference pass
Bringing ATMPs to the patients: How to take an integrated approach towards solving regulatory and market access hurdles
Keynotes
Nov 1312:20
Conference pass
Cell & gene therapy: Can we manufacture and commercialise in a sustainable way?
Keynotes
Nov 1312:20
Conference pass
Challenges of developing an orphan drug worldwide
Keynotes
Nov 1312:20
Conference pass
Developments in Eastern Europe: Unique challenges and opportunities
Keynotes
Nov 1312:20
Conference pass
From Endpoints to Endgame: Incorporating the diagnostic odyssey and patient journey in your clinical development plan
Keynotes
Nov 1312:20
Conference pass
How to build an ecosystem for rare diseases, from private to public
Keynotes
Nov 1312:20
Conference pass
Inclusion of “nontraditional” as well as “low and middle” income patient populations in all aspects of drug development
Keynotes
Nov 1312:20
Conference pass
Pricing & reimbursement for cell & gene therapies – Are the models really that different from normal rare disease models?
Keynotes
Nov 1312:20
Conference pass
Regulatory & operational implementation of the direct to patient trial management mode
Keynotes
Nov 1312:20
Conference pass
The US healthcare model: Increasing patient affordability and access for oncology treatment
Keynotes
Nov 1312:20
Conference pass
Unique challenges in Brazil for orphan drug access and pricing
Keynotes
Nov 1312:20
Conference pass
Use of registries on OMPs post launch registration: Experience from Germany
Keynotes
Nov 1314:15
Conference pass
Chair opening remarks
Clinical Development
Nov 1314:20
Conference pass
Pre-approval access, a key component of your strategic drug development and market access plan in rare and orphan disease – Why? When? How?
Access & Pricing
Nov 1314:20
Conference pass
Case study: How a biotech can successfully raise funds for rare disease drug development
Science & Strategy
Nov 1314:20
Conference pass
Artificial Intelligence: Promise & Reality
Precision Medicine
Nov 1314:20
Conference pass
Novartis: CAR T Innovation Journey
Cell & Gene Therapy
Nov 1314:20
Conference pass
Industrialization of gene therapy manufacturing
Manufacture
Nov 1314:45
Conference pass
Panel: Perspectives from the industry in early access strategies
Access & Pricing
Anant Murthy, Vice President Of Market Access And Pricing, Alnylam Pharmaceuticals
Nov 1314:45
Conference pass
Case study: Systematic drug re-innovation and clinical evidence in orphan diseases
Science & Strategy
Nov 1314:45
Conference pass
The use of artificial intelligence and machine learning to drive innovation for rare disease treatments
Precision Medicine
Nov 1314:45
Conference pass
Nov 1314:45
Conference pass
Developing robust manufacturing processes for novel gene therapies
Manufacture
- Overcoming manufacturing challenges faced by therapy developers- Effectively preparing for later stage trials and commercialization
Nov 1315:10
Conference pass
Patient reported outcomes measures: An interpretable measure of patient benefit to demonstrate clinical effectiveness
Clinical Development
Thomas Morel, Director, UCB Pharma
Nov 1315:10
Conference pass
How can we get high quality data from patients for precision medicine?
Precision Medicine
Nov 1315:10
Conference pass
Treating Fabry disease: Phase 2 clinical updates and expansion of clinical activities into other indications
Cell & Gene Therapy
Nov 1315:30
Conference pass
Panel: Commercial negotiations in HTA
Access & Pricing
Sheela Upadhyaya, Associate Director Hst, National Institute for Health and Care Excellence
Nov 1315:35
Conference pass
How can technology and patient-focused approaches accelerate clinical development? orted outcomes measures: An interpretable measure of patient benefit to demonstrate clinical effectiveness
Clinical Development
Nov 1315:35
Conference pass
Advancement of analytical tools for testing and characterization of AAV gene therapy products
Manufacture
Nov 1316:45
Conference pass
The RUDY study to inform novel biomarkers and therapeutic targets with patients
Clinical Development
Nov 1316:45
Conference pass
Tool for reducing uncertainties in evidence generation for specialised treatments for rare diseases: TRUST4RD
Access & Pricing
Tackling uncertainties for rare diseases - The use of RWE to improve access for patients
Karen Facey, Senior Research Fellow, University of Edinburgh
Nov 1316:45
Conference pass
Showcases
Science & Strategy
Synthetic plasmalogen-based therapy for the treatment of Rhizomelic Chondrodysplasia Punctata (RCDP) and other rare pediatric peroxisomal disorders
Nov 1316:45
Conference pass
Newborn screening for rare diseases: Early diagnosis, treatment essential
Precision Medicine
Nov 1316:45
Conference pass
Defining effective manufacturing & regulatory standards
Manufacture
Nov 1317:10
Conference pass
A partnership that lasts- key considerations when working with CROs on rare disease studies
Clinical Development
- Mapping out the road to success (Sponsor/CRO relationship, operational success, and ethical considerations)
- The importance of the patient: Patient advocacy
- Reducing patient burden
- Partnering and Trust
- Roles of CRO and Sponsor and defining scope
- Setting clear expectations for enrollment and retention: Site (KOls)/Patient identification, and patient recruitment
- Understanding evolving regulatory climate
- Ethical considerations
Nov 1317:10
Conference pass
What is the relationship between price and prevalence in non-oncology rare disease?
Access & Pricing
In the past, payers have always valued rarity in their pricing decisions. However, the environment is changing as the collective budget impact of rare diseases is increasing. Despite provision of alternative mechanisms for orphan drugs, payers are tougher on prices, negotiating rebates & setting budget impact thresholds; they are also scrutinising the patient population as a means to reduce uncertainty. So, with a recent flurry of headline-grabbing high prices in the non-oncology rare disease space, we have set out to investigate what is the relationship between prevalence and price
Nov 1317:10
Conference pass
Improving patient outcomes across the globe with the 100,000 genomes project rare disease programme
Precision Medicine
Nov 1317:10
Conference pass
Homologous recombination: A precise and nuclease-free approach to gene editing
Cell & Gene Therapy
Nov 1317:35
Conference pass
New models to run natural history studies and registries
Clinical Development
Perspectives from patients, CROs and regulators on sustainable RWE
Nov 1317:35
Conference pass
Decentralised digital trials in populations with high unmet need - Next generation approaches
Precision Medicine
Nov 1317:35
Conference pass
Translating a CRISPR platform into gene-edited cell therapies - the future is allogeneic
Cell & Gene Therapy
Nov 1317:35
Conference pass
Strategies and advances in lentiviral vector manufacturing and scale-up
Manufacture
Nov 1317:45
Conference pass
Panel: Critique of showcases & how to attract investment and progress your pipeline?
Science & Strategy
Private investment sources for orphan drugsInvestigating the funding opportunities available in Europe and globallyHow to attract larger players to collaborate
Nov 1318:00
Conference pass
Coming to America? How to position your orphan and rare product for launch in the United States
Access & Pricing
Nov 1318:00
Conference pass
What type of smartphone Apps are useful for patients? Empowerment through digital disease education created for patients with patients
Precision Medicine
Lucilla Franchetta Ortelli, Senior Manager, Alexion Pharma Germany Gmbh
Nov 1318:00
Conference pass
Harnessing the body’s natural DNA repair process to treat paediatric rare diseases
Cell & Gene Therapy
Nov 1318:00
Conference pass
Advances in cryopreservation technology to support the scalable supply requirements for cell and gene therapy
Manufacture
Create your personal agenda –check the favourite icon
Nov 1408:35
Conference pass
EUnetHTA update - Showcase of early dialogue and common assessment
Keynotes
- Hear from EMA’s scientific advice or accelerated approval and early consultation with EUnetHTA
- How does this route differ?
- Should companies continue with the usual EMA and access paths in parallel?
- Perspectives from industry who have engaged in early dialogue and their experience
- Perspectives from patients
Nov 1409:35
Conference pass
Transatlantic synergies between innovative payment models
Keynotes
- A global perspective on how split-cost and performance-based models work
- What are the quality criteria used?
- Investigating real-world learnings from European pricing models to incorporate into program designs
- What do payers think of transformative therapies like gene therapy?
Francis Pang, Vice-President Global Market Access, Orchard Therapeutics
Sheela Upadhyaya, Associate Director Hst, National Institute for Health and Care Excellence
Nov 1411:40
Conference pass
Improving healthcare communications in rare disease
Clinical Development
Gavin Jones, Director Of Rare Diseases, OPEN Health
Nov 1411:40
Conference pass
Are Europe’s collaborative efforts working? Beneluxa & Horizon scanning
Access & Pricing
Nov 1411:40
Conference pass
Novel Approaches to Clinical Trials in Rare Neurological Disorders
Precision Medicine
- Outcomes from OV101 STARS in Angelman syndrome and OV935 adults with developmental epileptic encephalopathies
Nov 1411:40
Conference pass
Germany and the CAR T cell therapy reimbursement model: Germany’s first outcomes-based deal
Cell & Gene Therapy
Nov 1411:40
Conference pass
Scaling manufacturing to deal with the demands of commercial cell & gene therapy products
Manufacture
Nov 1411:55
Conference pass
Patient-led organisation to successfully repurpose drugs
Science & Strategy
Nov 1411:55
Conference pass
Does cross border healthcare work for cell & gene therapy? The logistics and long-term treatment plan
Cell & Gene Therapy
Patient access for cell & gene therapies
Nov 1412:10
Conference pass
Update on V4+ initiative and ODs in Poland
Access & Pricing
MCDA as a tool in P&R decision making
Nov 1412:10
Conference pass
The promise of RNA interference (RNAi) therapeutics for orphan diseases
Precision Medicine
Nov 1412:10
Conference pass
Contrasting In-House and External Manufacturing Options
Manufacture
Nov 1414:10
Conference pass
The role of patient advocacy in ensuring access to effective and transformative therapies
Clinical Development
Nov 1414:10
Conference pass
Nordic HTA collaborations
Access & Pricing
Ulrika Vestin, Swedish Association of Local Authorities and Regions
Nov 1414:10
Conference pass
Genetic surgery: Allele-specific gene editing using engineered CRISPR nuclease
Precision Medicine
Nov 1414:10
Conference pass
Discover what payers really think of gene therapy
Cell & Gene Therapy
Nov 1414:40
Conference pass
Industry panel: How are we incorporating the patients in a meaningful way?
Clinical Development
Gail Moore, Director Global Patient Advocacy, Horizon Pharma
Sonali Chopra, Associate Director, Genentech
Nov 1414:40
Conference pass
Panel from our companies/organisations: what are the long-term implications of these alternative business models?
Science & Strategy
What are the differences to the more traditional model of pharma?What are the long-term implications?How do you collaborate, especially with very rare diseases to be sustainable?
Nov 1414:40
Conference pass
Panel: European Investment landscape for cell & gene therapy
Cell & Gene Therapy
Stijn Vanacker, Portfolio Manager, Robeco
Owen Smith, Principal, 4Bio Capital
Nov 1415:10
Conference pass
Therapeutic genome editing of Charcot-Marie-Tooth 1A disease
Precision Medicine
Nov 1415:10
Conference pass
How can advanced therapy companies make their manufacturing process more cost effective and sustainable?
Manufacture
Nov 1416:00
Conference pass
The impact of digital & computational tools on diagnostics and patient care
Keynotes
- How will new diagnostic technologies in genomics, sequencing and AI change the way patients access diagnostics?
- What impact will it have to physicians and at a hospital level?
- Looking into the future, will these advances mean that treatments will become more accessible for all?
Ryan Taft, Senior Director, Scientific Research, Illumina
Nov 1416:45
Conference pass
What are the real impacts & benefits of cross-border collaborations?
Keynotes
- Measurable effectiveness to patient access to orphan medicines
- How to navigate through Europe’s complex HTA landscape?
- Bringing together perspectives from multiple collaborations
Ulrika Vestin, Swedish Association of Local Authorities and Regions
last published: 27/Jun/19 15:45 GMT
Organiser
